NeuroPace, Inc. (NPCE)
Automate Your Wheel Strategy on NPCE
With Tiblio's Option Bot, you can configure your own wheel strategy including NPCE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NPCE
- Rev/Share 2.863
- Book/Share 0.5589
- PB 26.0525
- Debt/Equity 3.8439
- CurrentRatio 4.862
- ROIC -0.2032
- MktCap 484960607.0
- FreeCF/Share -0.5005
- PFCF -29.2444
- PE -20.1134
- Debt/Assets 0.6637
- DivYield 0
- ROE -1.366
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | NPCE | H.C. Wainwright | -- | Buy | -- | $18 | May 28, 2025 |
| Initiation | NPCE | UBS | -- | Buy | -- | $17 | Jan. 21, 2025 |
News
NeuroPace, Inc. (NPCE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Published: February 24, 2026 by: Zacks Investment Research
Sentiment: Negative
NeuroPace (NPCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026
Published: February 20, 2026 by: Business Wire
Sentiment: Neutral
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the fourth quarter of 2025 after market close on Tuesday, March 3, 2026. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). Investors interested in listening to the conference call may do so by accessin.
Read More
NeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference
Published: December 31, 2025 by: Business Wire
Sentiment: Neutral
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 44th Annual J.P. Morgan Healthcare Conference at 3:00pm PT on Wednesday, January 14, 2026, in San Francisco, CA. Management will also host investor meetings during the conference. The presentation will be accessible via live webcast here. A webcast replay will be available f.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
Published: July 02, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. ("NeuroPace" or the "Company") (NASDAQ: NPCE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
Published: June 27, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , June 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. ("NeuroPace" or the "Company") (NASDAQ: NPCE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. (“NeuroPace” or the “Company”) (NASDAQ: NPCE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
NPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law Firm
Published: June 22, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)---- $NPCE--NPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law Firm.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
Published: June 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. ("NeuroPace" or the "Company") (NASDAQ:NPCE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
Published: June 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. ("NeuroPace" or the "Company") (NASDAQ:NPCE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Shareholders to Connect
Published: June 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NeuroPace, Inc. ("NeuroPace" or "the Company") (NASDAQ:NPCE). Investors who purchased NeuroPace securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NPCE.
Read More
Potential Securities Fraud: Levi & Korsinsky Investigates NeuroPace, Inc. (NPCE)
Published: June 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of NeuroPace, Inc. ("NeuroPace, Inc.") (NASDAQ:NPCE) concerning possible violations of federal securities laws. NeuroPace issued a press release on May 27, 2025, "announc[ing] the preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for treatment of individuals with drug-resistant idiopathic generalized epilepsy (IGE).
Read More
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against NeuroPace, Inc. (NPCE) And Encourages Shareholders to Reach Out
Published: June 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NeuroPace, Inc. ("NeuroPace" or "the Company") (NASDAQ:NPCE). Investors who purchased NeuroPace securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NPCE.
Read More
Potential Securities Fraud: Levi & Korsinsky Investigates NeuroPace, Inc. (NPCE)
Published: June 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of NeuroPace, Inc. ("NeuroPace, Inc.") (NASDAQ:NPCE) concerning possible violations of federal securities laws. NeuroPace issued a press release on May 27, 2025, "announc[ing] the preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for treatment of individuals with drug-resistant idiopathic generalized epilepsy (IGE).
Read More
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against NeuroPace, Inc. (NPCE) and Encourages Shareholders to Learn More About the Investigation
Published: June 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NeuroPace, Inc. ("NeuroPace" or "the Company") (NASDAQ:NPCE). Investors who purchased NeuroPace securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NPCE.
Read More
Fraud Investigation: Levi & Korsinsky Investigates NeuroPace, Inc. (NPCE) on Behalf of Shareholders
Published: June 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of NeuroPace, Inc. ("NeuroPace, Inc.") (NASDAQ:NPCE) concerning possible violations of federal securities laws. NeuroPace issued a press release on May 27, 2025, "announc[ing] the preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for treatment of individuals with drug-resistant idiopathic generalized epilepsy (IGE).
Read More
NPCE ALERT: Ongoing Investigation Into NeuroPace, Inc. - Contact Levi & Korsinsky
Published: June 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of NeuroPace, Inc. ("NeuroPace, Inc.") (NASDAQ:NPCE) concerning possible violations of federal securities laws. NeuroPace issued a press release on May 27, 2025, "announc[ing] the preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for treatment of individuals with drug-resistant idiopathic generalized epilepsy (IGE).
Read More
NeuroPace, Inc. (NPCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Published: June 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NeuroPace, Inc. ("NeuroPace" or "the Company") (NASDAQ:NPCE). Investors who purchased NeuroPace securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NPCE.
Read More
Levi & Korsinsky Investigates NeuroPace, Inc. (NPCE) Over Possible Securities Fraud
Published: June 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of NeuroPace, Inc. ("NeuroPace, Inc.") (NASDAQ:NPCE) concerning possible violations of federal securities laws. NeuroPace issued a press release on May 27, 2025, "announc[ing] the preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for treatment of individuals with drug-resistant idiopathic generalized epilepsy (IGE).
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
Published: June 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. ("NeuroPace" or the "Company") (NASDAQ:NPCE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Did NeuroPace, Inc. (NPCE) Mislead Investors? Levi & Korsinsky Investigates
Published: June 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of NeuroPace, Inc. ("NeuroPace, Inc.") (NASDAQ:NPCE) concerning possible violations of federal securities laws. NeuroPace issued a press release on May 27, 2025, "announc[ing] the preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for treatment of individuals with drug-resistant idiopathic generalized epilepsy (IGE).
Read More
NeuroPace, Inc. (NPCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Published: June 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NeuroPace, Inc. ("NeuroPace" or "the Company") (NASDAQ:NPCE). Investors who purchased NeuroPace securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NPCE.
Read More
Ongoing Investigation into NeuroPace, Inc. (NPCE): Contact Levi & Korsinsky About Potential Fraud
Published: June 06, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of NeuroPace, Inc. ("NeuroPace, Inc.") (NASDAQ:NPCE) concerning possible violations of federal securities laws. NeuroPace issued a press release on May 27, 2025, "announc[ing] the preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for treatment of individuals with drug-resistant idiopathic generalized epilepsy (IGE).
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. (“NeuroPace” or the “Company”) (NASDAQ: NPCE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Fraud Investigation Opened: Levi & Korsinsky Investigates NeuroPace, Inc. (NPCE) on Behalf of Shareholders
Published: June 05, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of NeuroPace, Inc. ("NeuroPace, Inc.") (NASDAQ:NPCE) concerning possible violations of federal securities laws. NeuroPace issued a press release on May 27, 2025, "announc[ing] the preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for treatment of individuals with drug-resistant idiopathic generalized epilepsy (IGE).
Read More
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against NeuroPace, Inc. (NPCE) and Encourages Investors to Learn More About the Investigation
Published: June 05, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NeuroPace, Inc. ("NeuroPace" or "the Company") (NASDAQ:NPCE). Investors who purchased NeuroPace securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NPCE.
Read More
Did You Suffer Losses in NeuroPace, Inc. (NPCE)? Contact Levi & Korsinsky About Securities Fraud Claims
Published: June 05, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of NeuroPace, Inc. ("NeuroPace, Inc.") (NASDAQ:NPCE) concerning possible violations of federal securities laws. NeuroPace issued a press release on May 27, 2025, "announc[ing] the preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for treatment of individuals with drug-resistant idiopathic generalized epilepsy (IGE).
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
Published: June 05, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. ("NeuroPace" or the "Company") (NASDAQ:NPCE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Lost Money on NeuroPace, Inc. (NPCE)? Contact Levi & Korsinsky About Investigation
Published: June 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of NeuroPace, Inc. ("NeuroPace, Inc.") (NASDAQ:NPCE) concerning possible violations of federal securities laws. NeuroPace issued a press release on May 27, 2025, "announc[ing] the preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for treatment of individuals with drug-resistant idiopathic generalized epilepsy (IGE).
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
Published: June 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. ("NeuroPace" or the "Company") (NASDAQ:NPCE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
NPCE ALERT: Ongoing Investigation Into NeuroPace, Inc. - Contact Levi & Korsinsky
Published: June 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of NeuroPace, Inc. ("NeuroPace, Inc.") (NASDAQ:NPCE) concerning possible violations of federal securities laws. NeuroPace issued a press release on May 27, 2025, "announc[ing] the preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for treatment of individuals with drug-resistant idiopathic generalized epilepsy (IGE).
Read More
About NeuroPace, Inc. (NPCE)
- IPO Date 2021-04-22
- Website https://www.neuropace.com
- Industry Medical - Devices
- CEO Joel D. Becker
- Employees 184